Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 8:41 PM ET

Biotechnology

Company Overview of Therapix Biosciences Ltd.

Company Overview

Therapix Biosciences Ltd., a biopharmaceutical company, identifies and develops specialty biopharmaceuticals. It develops LP-306, a novel pharmaceutical based on cannabinoids for pain management; and TRX-318, an oral monoclonal antibody for the treatment of auto-immune and inflammatory diseases. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is based in Tel Aviv, Israel.

5 Azrieli Center (Square Tower)

27th Floor

Tel Aviv,  6702501

Israel

Founded in 2004

Phone:

972 3 616 7055

Fax:

972 3 616 7056

Key Executives for Therapix Biosciences Ltd.

Chief Executive Officer
Total Annual Compensation: $464.0K
Compensation as of Fiscal Year 2014.

Therapix Biosciences Ltd. Key Developments

Therapix Biosciences Ltd., Special/Extraordinary Shareholders Meeting, Jun 10, 2015

Therapix Biosciences Ltd., Special/Extraordinary Shareholders Meeting, Jun 10, 2015., at 10:00 Israel Standard Time.

Therapix Biosciences Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 11:30 AM

Therapix Biosciences Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 11:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Therapix Bio Names Jan Turek as Chief Executive Officer

Therapix Bio announced that Jan Turek has been named Chief Executive Officer, effective as of September 22, 2014. As CEO, he will lead the company's strategic growth initiatives, including the acquisition of and investment in cannabinoid-focused companies and technologies, and the development of these assets. Turek joins Therapix with over 30 years' experience in biotech and pharmaceutical executive leadership, product development, marketing and business development. As a Partner at TCG, LLC, he has been a senior strategy and transaction advisor to a number of large and small biopharmaceutical companies.

Similar Private Companies By Industry

Company Name Region
CARDIAPEX Ltd. Middle East/Africa
VAYA Pharma Inc. Middle East/Africa
Recogene Ltd. Middle East/Africa
Qray Middle East/Africa
Fertility Labs Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 3, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Therapix Biosciences Ltd., please visit www.therapixbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.